Boosting Regional health Economy Through Collaboration

The Burgundy-Franche-Comté region is witnessing a notable push to amplify its already robust health sector. At the heart of this initiative is Sentenov Dijon Bourgogne, a dynamic cluster designed to unify and elevate the region’s health companies. representing a collective of 150 enterprises, this ecosystem generates €1.5 billion in revenue and provides employment for 6,000 individuals. Sentenov Dijon Bourgogne aims to showcase this considerable health expertise and foster value creation both locally and internationally.

Strategic Partnerships Forged to Enhance Competitiveness

Born from the merger of Sentenov and BFCARE technopole in December 2024, Sentenov Dijon Bourgogne is actively pursuing numerous projects and collaborations. A recent round table discussion,titled Le Cluster Santé,a tool in the service of economic performance and the attractiveness of the territory, highlighted the cluster’s ambition and strategic direction.

Key Discussion Points at the Round Table:

• Developing business opportunities and enhancing regional visibility.
• Accelerating start-ups through Sentenov’s innovative programs.
• Learning from the experiences of triumphant health clusters across France.
• Elevating Sentenov Dijon Bourgogne’s national and international profile.

The round table served to emphasize Sentenov Dijon Bourgogne’s core strengths, including its comprehensive support system, the engagement of both private and public stakeholders, backing from public authorities, and strategic alliances. Two notable partnerships have already been established:

• Leem Partnership: focused on boosting competitiveness and promoting careers within the regional pharmaceutical sector.
• Genopole and Walter-Patriarche Partnership: Initiating Sentenov’Boost, a start-up acceleration program, with the first two Dijon-based ventures already selected.

leveraging Expertise and Expanding Resources

Drawing inspiration from established innovation hubs like Eurasanté in Lille and Nextmed in strasbourg,Sentenov Dijon Bourgogne is committed to providing dedicated support for innovation and entrepreneurship. To further enhance its capabilities, the cluster plans to expand its team with additional staff this year. This expansion will enable Sentenov Dijon Bourgogne to effectively implement action plans for its members and strengthen its partnerships.

Strategic Alliances: Leem and Genopole

During the round table, Sentenov Dijon Bourgogne formalized two pivotal partnerships that promise immediate benefits to its members.

Partnership with Leem

Leem, a prominent institution in the pharmaceutical industry, plays a crucial role in addressing future challenges.it acts as a liaison between regulatory bodies and pharmaceutical companies, addressing issues related to health economics, environmental concerns, labor regulations, and research. This partnership provides Sentenov Dijon Bourgogne members with access to expertise and up-to-date information, enabling them to address industrial, regulatory, and social challenges effectively.

This partnership with Leem acknowledges Sentenov Dijon Bourgogne’s vital role in supporting health companies within the Bourgogne-Franche-comté region.

Collaboration with Genopole and Walter-Patriarche

The collaboration with Genopole and Walter-Patriarche facilitates the launch of Sentenov’Boost, a program designed to support health start-ups. Genopole, established in 1998, has a proven track record of supporting over 300 start-ups. This initiative precedes the completion of Sentenov Dijon Bourgogne’s future Totem building, a dedicated space for innovation.

As France’s premier biocluster, Genopole allows us to initiate the acceleration of two first startups this year.

Fostering Innovation and Performance

These partnerships build upon years of dedicated effort by Sentenov Dijon Bourgogne and its founding members to foster innovation and enhance the performance of health companies. The collaboration with Leem enriches the cluster’s commissions with valuable content for its members, while the partnership with Genopole accelerates the progress of promising start-ups.

A Comprehensive Health Hub: Dijon Bourgogne’s Strengths

The Dijon Bourgogne region stands out as a comprehensive health ecosystem, encompassing the entire healthcare value chain. This region boasts a strong presence of international leaders across various market segments, making it a significant player in the global health arena. From innovative therapies to cutting-edge medical technologies, Dijon Bourgogne is fostering advancements that are shaping the future of healthcare.

Key Areas of Expertise

The region’s health sector demonstrates particular strength in the following areas:

• Wound Healing and Skin Pathologies: Companies like Urgo Medical, Cohesives, and Coluxia are pioneering advancements in skin wound treatment and related pathologies.
• Orthopedics: With companies such as Proteor, Movmedix, and Orthomedica, Dijon Bourgogne is at the forefront of orthopedic innovation.
• Transdermal Pharmaceutical delivery: Crossject,Adhexpharma,and Coluxia are developing innovative methods for delivering medications through the skin.
• Pharmaceutical Manufacturing: Companies like Delpharm, Astrea Pharma, and corden Pharma provide crucial pharmaceutical manufacturing services.
• Family Medication: Major players like Procter & gamble and Urgo Healthcare contribute considerably to the family medication market.
• Hospital Information Systems: CPage and Maincare are developing advanced systems to improve hospital operations and patient care.
• finding and Assessment of Innovative Therapies: Oncodesign Services, ICTA, and Vivexia offer services for the discovery and preclinical/clinical assessment of new therapies.
• Oncology and Inflammatory Diseases: Oncodesign Precision Medicine, inventiva, and H4 Orphan Pharma are focused on developing treatments for cancer and inflammatory conditions.

Academic and Research Powerhouse

Beyond its commercial strengths, Dijon Bourgogne benefits from prestigious academic research laboratories supported by public institutions.these include the Dijon Bourgogne CHU, Burgundy-Europe University, and the georges-François Leclerc Center (CGFL). Together, these institutions house approximately one thousand researchers, driving innovation and discovery in the health sector. This collaborative habitat fosters a synergistic relationship between research and industry, accelerating the translation of scientific breakthroughs into practical applications.

the impact of Sentenov Dijon Bourgogne stems from its role as a central hub dedicated to health, uniting all stakeholders, promoting health expertise, and facilitating ambitious projects.

Sentenov Dijon Bourgogne’s Strategic Priorities for 2025

Sentenov Dijon Bourgogne has outlined four key priorities for the year 2025, aimed at further strengthening the region’s health ecosystem and driving innovation.

Key Objectives for the Year

• Team Expansion: Strengthening the core team following the merger with BFCARE, and engaging ecosystem stakeholders in thematic commissions.
• Promoting the Ecosystem: Participating in major events such as Congress France Bioproduction, Santexpo, and Forum IA4Care to showcase the region’s capabilities.
• Supporting Innovation: Continuing to support innovative projects and start-ups in the health sector.
• Fostering Major Projects: Supporting the development of significant structuring projects like Powder on and Inano-T.

France’s Pharmaceutical Industry: A National Viewpoint

The strength of Dijon Bourgogne’s health ecosystem is mirrored by the robust pharmaceutical industry across France.Leem, the institution representing pharmaceutical companies in France, highlights the significant contributions of this sector to the national economy and healthcare landscape. According to recent data, the pharmaceutical industry in France comprises approximately 300 companies, employing nearly 100,000 people. These companies invest an estimated €3.9 billion annually in research and development, driving the discovery of new medicines and therapies. Leem plays a crucial role in upholding ethical standards, facilitating collaboration among its members, and advocating for the industry’s interests.

Leem’s role is to develop and enforce the ethics of the profession, to facilitate exchanges between its members, to defend their collective interests and to strengthen links with other health professions.

Leem

Genopole: A Hub for Genetics and Biotechnology

Genopole, a French biocluster dedicated to research in genetics and biotechnologies applied to health and the environment, further exemplifies France’s commitment to innovation in the life sciences. Located near Paris, Genopole brings together a diverse community of biotechnology companies, research laboratories, and technological platforms. Its mission is to foster the growth of biotechnology companies, facilitate technology transfer to the industrial sector, and promote advanced research and education in the life sciences. Genopole’s initiatives are supported by a consortium of public and private partners,including the State,the Ile-de-France region,and AFM-Téléthon.

Genopole’s objective: to create and support biotechnology companies and the transfer of technologies to the industrial sector, to promote the development of research in the life sciences, to develop high -level lessons in these areas.

Genopole

Walter: Shaping the Future of Work

Walter, an entity focused on the development and management of mixed-use spaces, plays a supporting role in the broader innovation ecosystem. Since 2019, Walter has been creating spaces that cater to the evolving needs of modern work environments. With a growing network of locations across multiple cities and countries, Walter provides flexible and collaborative workspaces for a diverse community of users.

Since 2019, its objective is to meet the evolutionary and hybrid needs of new working methods.

Walter